Blister-Packaged Tablets:


Diethylcarbamazine (DEC) for lymphatic filariasis and tropical pulmonary eosinophilia


100 mg tiny tablet



Ivermectin (IVM) for onchocerciasis, lymphatic filariasis, scabies, strongyloidiasis, mansonelliasis, and malaria transmission


3 mg dissolvable



Albendazole (ALB) for soil transmitted helminths (ascariasis, trichuriasis, and hookworm infection), lymphatic filariasis, oesophagostomiasis, and strongyloidiasis


400 mg chewable


Powder and Solvent for Suspension for Injection:


Benzathine Penicillin (BPG) for congenital syphilis, rheumatic heart disease, erysipelas, yaws, and pinta


1.2M U IM and 2.4 U IM vials


Blister-Packaged Soft Gelatin Capsules:


Vitamin A (Vit A) for blindness and related mortality, respiratory disease, and other infections


100,000 IU and 200,000 IU liquid



The usual approach to community-based mass drug administration is for tablets to be distributed from shared bottles without labels or instructions. As a result, patients have a lack of trust and effective coverage is poor. Today, Bend Biomedical blister-packaged medicines are attractive for both low- and middle-income countries. Our packaging model can be used to provide critically needed medicines for neglected populations around the world.


Community-based mass drug administration with our blister-packaged albendazole or ivermectin tablets is an opportune time to distribute a high-dose vitamin A capsule to children under five.


Most of our disease targets are for “Neglected Tropical Diseases,” a group of infections that are common in the tropics and subtropics. These diseases are poverty-related and impair or permanently disable millions of people every year, often making it difficult to be productive in school, to marry, and to earn a living. They often cause life-long physical pain and social stigmatization.
 
We participate in a process known as World Health Organization (WHO) prequalification of medicines, a service provided by WHO to assess the quality, safety and efficacy of medicinal products. Only essential medicines qualify. Countries are now expressing a preference for WHO prequalified generics.

Drugs and diseases are listed for informational purposes only. Consult your local medical authority for advice.


Sources

Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. Geneva: World Health Organization; 2017. 9789241550161-eng.

Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures. Geneva: World Health Organization; 2016 (updated 2020). 9789241510011-eng.


Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization; 2017. 9789241550116-eng.


The Global elimination of congenital syphilis: rationale and strategy for action. Geneva, World Health Organization, 2007. 9789241595858_eng. 


Guideline: Vitamin A supplementation in infants and children 6-59 months of age. Geneva, World Health Organization, 2011. 9789241501767-eng.